Introduction: Signal transduction therapy - 10 Years later

Seminars in Cancer Biology

Volumn 14, Issue 4, 2004, Pages 219-221

  Levitzki, A ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AGL 2043; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFLAMMATORY AGENT; CETUXIMAB; ERLOTINIB; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAPAMYCIN; RECEPTOR BLOCKING AGENT; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYRPHOSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

CHRONIC MYELOID LEUKEMIA; DRUG ELUTING STENT; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 3042517341     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2004.04.007     Document Type: Editorial

References (12)

1. Levitzki A. Signal-transduction therapy. A novel approach to disease management. Eur. J. Biochem. 226:1994;1-13
2. Lydon N.B., Druker B.J. Lessons learned from the development of imatinib. Leuk. Res. 28(Suppl 1):2004;29-38
3. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:2003;4342-4349
4. Mauro M.J., Druker B.J., Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk. Res. 28(Suppl 1):2004;71-73
5. Levitzki A. From epinephrine to cyclic AMP. Science. 241:1988;800-806
6. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225
8. Zwick E., Hackel P.O., Prenzel N., Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20:1999;408-412
9. Banai S, Chorny M, Gertz SD, Fishbein I, Gao J, Perez L, et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Cardiovascular Res, in press.
10. Reimold A.M. TNFalpha as therapeutic target: new drugs, more applications. Curr. Drug Targets Inflamm. Allergy. 1:2002;377-392
11. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin. Investig. Drugs. 12:2003;1087-1095
12. Levitzki A. EGF receptor as a therapeutic target. Lung Cancer. 41(Suppl 1):2003;9-14